Harnessing dual-channel probiotics to synergistically correct intestinal and vaginal dysbiosis after antibiotic disruption.

ABSTRACT: Antibiotics are widely used to treat infectious diseases, yet antibiotic therapy has been shown to disrupt symbiotic microbiota. Notably, the dosage and duration of antibiotic use for specific infections may exert detrimental effects on microbiota in non-infected sites. Here, we propose a dual-channel probiotic delivery strategy to address gut and vaginal dysbiosis caused by antibiotic therapies. In a Helicobacter pylori infection model, oral administration of Limosilactobacillus reuteri NCU-15 alleviated gastritis and protected the intestinal barrier and microbiota. In a vaginal dysbiosis model, intravaginal delivery of Lactobacillus crispatus NCU-23 reduced local inflammation and apoptosis, restoring vaginal microbial homeostasis. In the entero-vaginal disordered mice, dual-channel probi

SUBMITTER: Zhao X 

PROVIDER: S-EPMC12378221 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature